Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:APLT

Applied Therapeutics - APLT Stock Forecast, Price & News

$0.90
+0.01 (+0.78%)
(As of 11/25/2022 08:57 PM ET)
Add
Compare
Today's Range
$0.84
$0.95
50-Day Range
$0.54
$1.17
52-Week Range
$0.50
$11.87
Volume
286,400 shs
Average Volume
373,007 shs
Market Capitalization
$43.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.05

Applied Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,132.0% Upside
$11.05 Price Target
Short Interest
Healthy
0.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$52,340 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.34) to ($1.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Medical Sector

58th out of 1,044 stocks

Pharmaceutical Preparations Industry

25th out of 510 stocks

APLT stock logo

About Applied Therapeutics (NASDAQ:APLT) Stock

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Receive APLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLT Stock News Headlines

Recap: Applied Therapeutics Q2 Earnings
Nasdaq Jumps Over 100 Points; Applied Therapeutics Shares Plummet
Applied Therapeutics launches stock offering
Applied Therapeutics GAAP EPS of -$0.88
See More Headlines
Receive APLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLT Company Calendar

Last Earnings
11/12/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLT
Fax
N/A
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.05
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$2.25
Forecasted Upside/Downside
+1,466.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-105,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.20 per share

Miscellaneous

Free Float
39,889,000
Market Cap
$43.10 million
Optionable
Not Optionable
Beta
1.53

Key Executives

  • Dr. Shoshana Shendelman Ph.D.Dr. Shoshana Shendelman Ph.D. (Age 43)
    Chair of the Board of Directors, Founder, Pres, CEO & Sec.
    Comp: $588.47k
  • Dr. Riccardo Perfetti M.D.Dr. Riccardo Perfetti M.D. (Age 62)
    Ph.D., Chief Medical Officer
    Comp: $792.25k
  • Mr. Chids Mahadevan (Age 52)
    Sr. VP of Fin. & Interim Principal Financial Officer
  • Mr. Steven Ortega (Age 36)
    Chief Accounting Officer
  • Mr. Adam Hansard (Age 46)
    Chief Commercial Officer













APLT Stock - Frequently Asked Questions

Should I buy or sell Applied Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APLT shares.
View APLT analyst ratings
or view top-rated stocks.

What is Applied Therapeutics' stock price forecast for 2023?

2 brokers have issued 1 year price targets for Applied Therapeutics' shares. Their APLT share price forecasts range from $2.25 to $23.00. On average, they expect the company's stock price to reach $11.05 in the next twelve months. This suggests a possible upside of 1,131.9% from the stock's current price.
View analysts price targets for APLT
or view top-rated stocks among Wall Street analysts.

How have APLT shares performed in 2022?

Applied Therapeutics' stock was trading at $8.95 at the beginning of the year. Since then, APLT shares have decreased by 90.0% and is now trading at $0.8970.
View the best growth stocks for 2022 here
.

When is Applied Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our APLT earnings forecast
.

How were Applied Therapeutics' earnings last quarter?

Applied Therapeutics, Inc. (NASDAQ:APLT) issued its quarterly earnings results on Friday, November, 12th. The company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.06.

What other stocks do shareholders of Applied Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS) and Raytheon Technologies (RTX).

When did Applied Therapeutics IPO?

(APLT) raised $60 million in an initial public offering on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager.

What is Applied Therapeutics' stock symbol?

Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."

Who are Applied Therapeutics' major shareholders?

Applied Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (3.58%), BlackRock Inc. (1.10%), Vanguard Group Inc. (0.94%), Renaissance Technologies LLC (0.70%), Two Sigma Advisers LP (0.52%) and Ergoteles LLC (0.11%). Insiders that own company stock include Charles Silberstein, Chids Mahadevan, Joel S Marcus, Leslie D Funtleyder, Real Estate Equitie Alexandria, Riccardo Perfetti, Shoshana Shendelman and Stacy J Kanter.
View institutional ownership trends
.

How do I buy shares of Applied Therapeutics?

Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Applied Therapeutics' stock price today?

One share of APLT stock can currently be purchased for approximately $0.90.

How much money does Applied Therapeutics make?

Applied Therapeutics (NASDAQ:APLT) has a market capitalization of $43.11 million. The company earns $-105,580,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis.

How can I contact Applied Therapeutics?

Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The official website for the company is www.appliedtherapeutics.com. The company can be reached via phone at (212) 220-9226 or via email at maeve@argotpartners.com.

This page (NASDAQ:APLT) was last updated on 11/28/2022 by MarketBeat.com Staff